Deciphera forges exclusive distribution deal with Genesis Pharma

OGphoto/iStock via Getty Images Deciphera Pharmaceuticals ( NASDAQ: DCPH ) has signed an exclusive distribution agreement with Genesis Pharma to commercialize its kinase inhibitor Ripretinib in 14 European markets in Central and Eastern Europe. The drug is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with three or more kinase inhibitors, including imatinib.

Under the terms of the agreement, Genesis Pharma will exclusively commercialize Ripretinib in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia. More on Deciphera Pharmaceuticals Deciphera: Upside Potential For The Patient Investor Deciphera Pharmaceuticals: Moving The Needle Where It Counts Deciphera Pharmaceuticals, Inc.

(DCPH) Q3 2023 Earnings Call Transcript Jones Research upgrades Deciphera to buy from hold Deciphera stock climbs as trial for tumor therapy succeeds (update).